Inactief instrument

Andere talen VentriPoint Diagnostics Ltd. Toronto S.E.

Aandelen

VPT

CA92281P2008

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Ventripoint to Present its AI-enhanced Cardiac Ultrasound Technology to B.C. and Canadian Health Care Leaders at The Data Effect	24/06
Ventripoint Diagnostics Ltd. Appoints Matt Dobson as Marketing Director	13/06
Ventripoint Welcomes Matt Dobson as Marketing Director to Guide Market Development and Product Management	13/06
Ventripoint Diagnostics Announces Shareholder Update and Teleconference	11/06
Ventripoint Diagnostics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	31/05
Ventripoint Diagnostics Ltd. Submits Next Generation of Software, VMS+4.0, to the U.S. Food and Drug Administration	06/05
Ventripoint's Next Generation, AI-powered Heart-scanning Technology Submitted to U.S Food and Drug Administration	06/05
Duke University Health Center Purchases Ventripoint's AI Heart-Scan Technology	01/05
Duke University Health Center -- One of America's Top Heart-care Institutions and Innovators -- Purchases Ventripoint's AI Heart-scan Technology	01/05
Ventripoint Diagnostics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	30/04
VentriPoint Diagnostics Ltd. announced that it expects to receive CAD 3 million in funding	11/04
Ventripoint Diagnostics Provides Corporate Update and Announces Conference Call	28/03
Ventripoint Diagnostics Ltd. Releases Significant Upgrade to the Design and Function of Its Whole-Heart Analysis System (VMS+3.2)	04/03
Enhanced Design Breakthrough Makes Ventripoint's VMS+ Even Simpler to Use	04/03
Ventripoint Diagnostics Ltd. Showcases A.I. Powered Heart-Scanning Technology at International Cardiology Conferences	20/02
Ventripoint Successfully Showcases A.I.-Powered Heart-Scanning Technology at Prestigious International Cardiology Conferences	20/02
Ventripoint Announces Changes to The Board of Directors	13/02
Ventripoint Diagnostics Ltd. Appoints Hugh Macnaught as Interim CEO	05/02
Ventripoint Diagnostics Ltd. Appoints Hugh Macnaught as President	05/02
Ventripoint Begins 2024 with Leadership Change	05/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen VentriPoint Diagnostics Ltd. Toronto S.E.

Aandelen

VPT

CA92281P2008

Andere talen

Filters